BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23329390)

  • 1. The contribution of cell phenotype to the behavior of gastric cancer.
    Solcia E; Klersy C; Vanoli A; Grillo F; Manca R; Tava F; Luinetti O; Fiocca R
    Gastric Cancer; 2013 Oct; 16(4):462-71. PubMed ID: 23329390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemically detectable Cdx2 is present in intestinal phenotypic elements in early gastric cancers of both differentiated and undifferentiated types, with no correlation to non-neoplastic surrounding mucosa.
    Mizoshita T; Tsukamoto T; Inada K; Ogasawara N; Hirata A; Kato S; Joh T; Itoh M; Yamamura Y; Tatematsu M
    Pathol Int; 2004 Jun; 54(6):392-400. PubMed ID: 15144397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic and immunohistochemical study on early gastric signet-ring cell carcinoma].
    Xiong ZF; Xiao H; Tan YS
    Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):442-6. PubMed ID: 21055171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis.
    Mizoshita T; Tsukamoto T; Nakanishi H; Inada K; Ogasawara N; Joh T; Itoh M; Yamamura Y; Tatematsu M
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):727-34. PubMed ID: 14557879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis.
    Fan Z; Li J; Dong B; Huang X
    Clin Cancer Res; 2005 Sep; 11(17):6162-70. PubMed ID: 16144916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer.
    Zhang X; Tsukamoto T; Mizoshita T; Ban H; Suzuki H; Toyoda T; Tatematsu M
    Oncol Rep; 2009 Mar; 21(3):609-13. PubMed ID: 19212618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer.
    Zhang Q; Ye Z; Yang Q; He X; Wang H; Zhao Z
    World J Surg Oncol; 2012 Jun; 10():103. PubMed ID: 22681645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis.
    Lopes N; Bergsland C; Bruun J; Bjørnslett M; Vieira AF; Mesquita P; Pinto R; Gomes R; Cavadas B; Bennett E; Pereira L; Lothe RA; Almeida R; David L
    Gastric Cancer; 2020 Sep; 23(5):811-823. PubMed ID: 32215766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage.
    Chiaravalli AM; Cornaggia M; Furlan D; Capella C; Fiocca R; Tagliabue G; Klersy C; Solcia E
    Virchows Arch; 2001 Aug; 439(2):158-69. PubMed ID: 11561756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features.
    Wang RQ; Fang DC
    J Clin Pathol; 2003 May; 56(5):378-84. PubMed ID: 12719460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastric Cancer With Primitive Enterocyte Phenotype: An Aggressive Subgroup of Intestinal-type Adenocarcinoma.
    Yamazawa S; Ushiku T; Shinozaki-Ushiku A; Hayashi A; Iwasaki A; Abe H; Tagashira A; Yamashita H; Seto Y; Aburatani H; Fukayama M
    Am J Surg Pathol; 2017 Jul; 41(7):989-997. PubMed ID: 28505005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations.
    Schildberg CW; Abba M; Merkel S; Agaimy A; Dimmler A; Schlabrakowski A; Croner R; Leupold JH; Hohenberger W; Allgayer H
    Adv Med Sci; 2014 Mar; 59(1):142-6. PubMed ID: 24797991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal expression of adhesion protein Bves is associated with gastric cancer progression and poor survival.
    Luo D; Huang H; Lu ML; Zhao GF; Chang J; Zheng MY; Wang Y
    Pathol Oncol Res; 2012 Apr; 18(2):491-7. PubMed ID: 22109561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of serum response factor is correlated with poor prognosis in patients with gastric cancer.
    Yin J; Lv X; Hu S; Zhao X; Liu Q; Xie H
    Hum Pathol; 2019 Mar; 85():10-17. PubMed ID: 30500416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Intestinal Stem Cell Marker SMOC2 Is an Independent Prognostic Marker Associated With Better Survival in Gastric Cancer.
    Hyun CL; Park SJ; Kim HS; Song HJ; Kim HU; Lee C; Lee DH; Maeng YH; Kim YS; Jang B
    Anticancer Res; 2021 Jul; 41(7):3689-3698. PubMed ID: 34230168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The overexpression of AP-4 as a prognostic indicator for gastric carcinoma.
    Xinghua L; Bo Z; Yan G; Lei W; Changyao W; Qi L; Lin Y; Kaixiong T; Guobin W; Jianying C
    Med Oncol; 2012 Jun; 29(2):871-7. PubMed ID: 21336989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric and intestinal phenotypic marker expression in gastric carcinomas and its prognostic significance: immunohistochemical analysis of 136 lesions.
    Tajima Y; Shimoda T; Nakanishi Y; Yokoyama N; Tanaka T; Shimizu K; Saito T; Kawamura M; Kusano M; Kumagai K
    Oncology; 2001; 61(3):212-20. PubMed ID: 11574777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma.
    Lin T; Ding YQ; Li JM
    Med Oncol; 2012 Jun; 29(2):878-85. PubMed ID: 21336986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower- and higher-grade subtypes of diffuse gastric cancer.
    Chiaravalli AM; Klersy C; Tava F; Manca R; Fiocca R; Capella C; Solcia E
    Hum Pathol; 2009 Nov; 40(11):1591-9. PubMed ID: 19540560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beclin 1 expression is an independent prognostic factor for gastric carcinomas.
    Yu M; Gou WF; Zhao S; Xiao LJ; Mao XY; Xing YN; Takahashi H; Takano Y; Zheng HC
    Tumour Biol; 2013 Apr; 34(2):1071-83. PubMed ID: 23334926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.